Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and ...

Vaccine stocks have struggled since RFK Jr.'s appointment to health secretary, with Moderna and Pfizer seeing the deepest ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good entry point for investors, according to Piper Sandler. Piper Sandler, which reiterated Overweight rating on Moderna, ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...